Clinical trial
High-Dose Cyclophosphamide for Steroid Refractory GVHD
NCT00492921 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00492921 |
|---|---|
| Title | High-Dose Cyclophosphamide for Steroid Refractory GVHD |
| Official title | High-Dose Cyclophosphamide in Treating Patients With Acute Graft-Versus-Host Disease That Did Not Respond to Steroid Therapy |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease |
| Intervention type | Drug |
| Interventions | Cyclophosphamide |
| Enrollment | 12 |
| Start date | May 1, 2007 |
| Primary completion | Jan 1, 2013 |
| Completion | Jan 1, 2013 |
| First posted | Jun 27, 2007 |
| Last update posted | Sep 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: